Significance of treatment response when managing patients with primary central nervous system lymphoma

References

• Kluin PM, Deckert M, Ferry JA. Primary diffuse large B-cell lymphoma of the CNS. In: Swerdlow SH, Campo E, Harris NL, editors. World Health Organization classification of tumours pathology and genetics of tumours of the haematopoietic and lymphoid tissues. Lyon (France): IARC Press; 2008. p. 240–241.
   Google Scholar
• O'Neill BP, Decker PA, Tieu C, et al. The changing incidence of primary central nervous system lymphoma is driven primarily by the changing incidence in young and middle-aged men and differs from time trends in systemic diffuse large B-cell non-Hodgkin's lymphoma. Am J Hematol. 2013;88:997–1000.
   PubMed Web of Science ®Google Scholar
• Villano JL, Koshy M, Shaikh H, et al. Age, gender, and racial differences in incidence and survival in primary CNS lymphoma. Br J Cancer. 2011;105:1414–1418.
   PubMed Web of Science ®Google Scholar
• Abrey LE, Yahalom J, DeAngelis LM. Treatment for primary CNS lymphoma: the next step. J Clin Oncol. 2000;18:3144–3150.
   PubMed Web of Science ®Google Scholar
• Bessell EM, Lopez-Guillermo A, Villa S, et al. Importance of radiotherapy in the outcome of patients with primary CNS lymphoma: an analysis of the CHOD/BVAM regimen followed by two different radiotherapy treatments. J Clin Oncol. 2002;20:231–236.
   PubMed Web of Science ®Google Scholar
• Xie H, Dahiya S, Murphy ES, et al. Primary central nervous system lymphoma in the elderly: the Cleveland clinic experience. Anticancer Res. 2013;33:3251–3258.
   PubMed Web of Science ®Google Scholar
• Omuro A, Taillandier L, Chinot O, et al. Primary CNS lymphoma in patients younger than 60: can whole-brain radiotherapy be deferred? J Neurooncol. 2011;104:323–330.
   PubMed Web of Science ®Google Scholar
• Omuro AM, Ben-Porat LS, Panageas KS, et al. Delayed neurotoxicity in primary central nervous system lymphoma. Arch Neurol. 2005;62:1595–1600.
   PubMed Web of Science ®Google Scholar
• Harder H, Holtel H, Bromberg JE, et al. Cognitive status and quality of life after treatment for primary CNS lymphoma. Neurology. 2004;62:544–547.
   PubMed Web of Science ®Google Scholar
• Correa DD, DeAngelis LM, Shi W, et al. Cognitive functions in survivors of primary central nervous system lymphoma. Neurology. 2004;62:548–555.
   PubMed Web of Science ®Google Scholar
• Thiel E, Korfel A, Martus P, et al. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial. Lancet Oncol. 2010;11:1036–1047.
   PubMed Web of Science ®Google Scholar
• Kerbauy MN, Moraes FY, Lok BH, et al. Challenges and opportunities in primary CNS lymphoma: a systematic review. Radiother Oncol. 2017;122:352–361.
   PubMed Web of Science ®Google Scholar
• Morris PG, Correa DD, Yahalom J, et al. Rituximab, methotrexate, procarbazine, and vincristine followed by consolidation reduced-dose whole-brain radiotherapy and cytarabine in newly diagnosed primary CNS lymphoma: final results and long-term outcome. J Clin Oncol. 2013;31:3971–3979.
   PubMed Web of Science ®Google Scholar
• Ferreri AJ, Cwynarski K, Pulczynski E, et al. Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial. Lancet Haematol. 2016;3:e217–e227.
   PubMed Web of Science ®Google Scholar
• Ferreri AJM, Cwynarski K, Pulczynski E, et al. Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial. Lancet Haematol. 2017;4:e510–e523.
   PubMed Web of Science ®Google Scholar
• Houillier C, Taillandier L, Lamy T, et al. Whole brain radiotherapy (WBRT) versus intensive chemotherapy with haematopoietic stem cell rescue (IC + HCR) for primary central nervous system lymphoma (PCNSL) in young patients: an intergroup Anocef-Goelams randomized phase II trial (PRECIS). Blood. 2016;128:782–782.
   Web of Science ®Google Scholar
• Abrey LE, Batchelor TT, Ferreri AJ, et al. Report of an international workshop to standardize baseline evaluation and response criteria for primary CNS lymphoma. J Clin Oncol. 2005;23:5034–5043.
   PubMed Web of Science ®Google Scholar
• Ferreri AJ, Blay JY, Reni M, et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience. J Clin Oncol. 2003;21:266–272.
   PubMed Web of Science ®Google Scholar
• Pels H, Schmidt-Wolf IG, Glasmacher A, et al. Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy. J Clin Oncol. 2003;21:4489–4495.
   PubMed Web of Science ®Google Scholar
• Abrey LE, Ben-Porat L, Panageas KS, et al. Primary central nervous system lymphoma: the Memorial Sloan-Kettering Cancer Center prognostic model. J Clin Oncol. 2006;24:5711–5715.
   PubMed Web of Science ®Google Scholar
• Schuurmans M, Bromberg JE, Doorduijn J, et al. Primary central nervous system lymphoma in the elderly: a multicentre retrospective analysis. Br J Haematol. 2010;151:179–184.
   PubMed Web of Science ®Google Scholar
• Korfel A, Martus P, Nowrousian MR, et al. Response to chemotherapy and treating institution predict survival in primary central nervous system lymphoma. Br J Haematol. 2005;128:177–183.
   PubMed Web of Science ®Google Scholar
• Kim YR, Kim SH, Chang JH, et al. Early response to high-dose methotrexate, vincristine, and procarbazine chemotherapy-adapted strategy for primary CNS lymphoma: no consolidation therapy for patients achieving early complete response. Ann Hematol. 2014;93:211–219.
   PubMed Web of Science ®Google Scholar
• Rubenstein JL, Hsi ED, Johnson JL, et al. Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). J Clin Oncol. 2013;1;31:3061–3068.
   Web of Science ®Google Scholar
• Schorb E, Finke J, Ferreri AJ, et al. High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma–a randomized phase III trial (MATRix). BMC Cancer. 2016;16:21–282.
   PubMed Web of Science ®Google Scholar
• Petereit HF, Rubbert-Roth A. Rituximab levels in cerebrospinal fluid of patients with neurological autoimmune disorders. Mult Scler. 2009;15:189–192.
   PubMed Web of Science ®Google Scholar
• Jahnke K, Doolittle ND, Muldoon LL, et al. Implications of the blood-brain barrier in primary central nervous system lymphoma. Neurosurgical Focus. 2006;21:17134113.
   Google Scholar
• Kansara R, Shenkier TN, Connors JM, et al. Rituximab with high-dose methotrexate in primary central nervous system lymphoma. Am J Hematol. 2015;90:1149–1154.
   PubMed Web of Science ®Google Scholar
• Mocikova H, Pytlik R, Sykorova A, et al. Role of rituximab in treatment of patients with primary central nervous system lymphoma: a retrospective analysis of the Czech lymphoma study group registry. Leuk Lymphoma. 2016;57:2777–2783.
   PubMed Web of Science ®Google Scholar